Top

General Thoracic and Cardiovascular Surgery

Published in:

01-11-2014 | Original Article

Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus

Authors: Masayuki Watanabe, Shinji Mine, Kazuhiko Yamada, Hironobu Shigaki, Yoshifumi Baba, Naoya Yoshida, Kiyoshi Kajiyama, Noriko Yamamoto, Takeshi Sano, Hideo Baba

Published in: General Thoracic and Cardiovascular Surgery | Issue 11/2014

Abstract

Objective

The aim of this study was to determine the significance of lymphadenectomy for recurrence after treatment for esophageal squamous cell carcinoma.

Methods

Short- and long-term outcomes of 24 patients who underwent lymphadenectomy for recurrence in 3 hospitals between April 2004 and March 2013 were retrospectively analyzed. There were 17 cases with lymph node recurrence after esophagectomy (11 cervical, 4 mediastinal, and 2 abdominal node recurrences) and 7 cases with remnant or recurrent lymphatic diseases after definitive chemoradiotherapy (3 cervical, 1 mediastinal, and 3 abdominal node recurrences).

Results

Three minor complications were observed among 24 patients and the median postoperative hospital stay was 7 days. The 3-year progression-free and overall survivals of patients who underwent secondary lymphadenectomy for recurrence after esophagectomy were 51.5 and 75.5 %, respectively. The overall survival of patients with cervical node recurrence was significantly better than that of patients with mediastinal or abdominal node recurrence in this group (P = 0.0097). The median progression-free and overall survivals of patients who underwent salvage lymphadenectomy after definitive chemoradiotherapy were 2 and 15 months, respectively. Although only 1 patient experienced local recurrence after secondary lymphadenectomy, locoregional failures occurred in 6 of 7 patients who underwent salvage lymphadenectomy after definitive chemoradiotherapy.

Conclusion

Secondary or salvage lymphadenectomy can be performed safely in the selected patients. Secondary lymphadenectomy achieves locoregional disease control and results in a favorable long-term outcome, particularly for cervical node recurrence. Further large-scale cohort studies are needed to determine the prognostic significance of salvage lymphadenectomy after definitive chemoradiotherapy.

Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220:364–73.PubMedCrossRefPubMedCentral

Cai WJ, Xin PL. Pattern of relapse in surgical treated patients with thoracic esophageal squamous cell carcinoma and its possible impact on target delineation for postoperative radiotherapy. Radiother Oncol. 2010;96:104–7.PubMedCrossRef

Shim YM, Kim HK, Kim K. Comparison of survival and recurrence pattern between two-field and three-field lymph node dissections for upper thoracic esophageal squamous cell carcinoma. J Thorac Oncol. 2010;5:707–12.PubMedCrossRef

Watanabe M, Nishida K, Kimura Y, Kiyazaki M, Baba H. Salvage lymphadenectomy for cervical lymph node recurrence after esophagectomy for squamous cell carcinoma of the thoracic esophagus. Dis Esophagus. 2012;25:62–6.PubMedCrossRef

Shitara K, Muro K. Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. Gastrointest Cancer Res. 2009;3:66–72.PubMedPubMedCentral

Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–43.PubMedCrossRef

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–90.PubMedCrossRef

Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.PubMed

Toh Y, Oki E, Minami K, Okamura T. Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic value. Esophagus. 2010;7:37–43.CrossRef

10.

Kato H, Fukuchi M, Miyazaki T, Nakajima M, Kimura H, Faried A, et al. Classification of recurrent esophageal cancer after radical esophagectomy with two- or three-field lymphadenectomy. Anticancer Res. 2005;25:3461–7.PubMed

11.

Smit JK, Pultrum BB, van Dullemen HM, van Dam GM, Groen H, Plukker JT. Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy. Am J Surg. 2010;200:446–53.PubMedCrossRef

12.

Nakamura T, Ota M, Narumiya K, Sato T, Ohki T, Yamamoto M, et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008;15:2451–7.PubMedCrossRef

13.

Yano M, Doki Y, Miyashiro I, Kishi K, Noura S, Eguchi H, et al. Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus. 2006;19:73–7.PubMedCrossRef

14.

Swisher SG, Wynn P, Putnam LB, Mosheim MB, Correa AM, Komaki RR, et al. Salvage esophagectomy for recurrent tumors after definitive chemoradiotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–83.PubMedCrossRef

15.

Tachimori Y. Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg. 2009;57:71–8.PubMedCrossRef

16.

Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, et al. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol. 2009;100:442–6.PubMedCrossRef

17.

Sakai M, Suzuki S, Sano A, Tanaka N, Inose T, Sohda M, et al. Significance of lymph node capsular invasion in esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:1911–7.PubMedCrossRef

18.

Tallinger CMR, Ruderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 2011;29:4709–17.CrossRef

Title: Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus
Authors: Masayuki Watanabe
Shinji Mine
Kazuhiko Yamada
Hironobu Shigaki
Yoshifumi Baba
Naoya Yoshida
Kiyoshi Kajiyama
Noriko Yamamoto
Takeshi Sano
Hideo Baba
Publication date: 01-11-2014
Publisher: Springer Japan
Published in: General Thoracic and Cardiovascular Surgery / Issue 11/2014
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI: https://doi.org/10.1007/s11748-014-0444-4

2024 ASCO Annual Meeting

Springer Medicine

Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus

Abstract

Objective

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2014

Donald Nixon Ross FRCS, FRCP (4 October 1922–7 July 2014)—and we called him Mr. Ross

Current status of induction treatment for N2-Stage III non-small cell lung cancer

Off-pump coronary surgery: current justifications

Leakage test during mitral valve repair

Aortic valve replacement in an elderly patient with factor XI deficiency

Cyclin-dependent kinase inhibitors, p16 and p27, demonstrate different expression patterns in thymoma and thymic carcinoma